We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Joint Misses Q1 Earnings Estimates on Rising Expenses
Read MoreHide Full Article
The Joint Corp. (JYNT - Free Report) shares have declined 4.2% since the company reported first-quarter 2025 results on May 8. Its weaker-than-expected earnings were caused by increased expenses under different heads, partially offset by higher system-wide sales.
JYNT reported an adjusted loss of 3 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 2 cents. However, the bottom line remained stable year over year.
Revenues increased 7% year over year to $13.1 million. The top line surpassed the consensus mark by 2.5%.
Royalty fees advanced 6.4% year over year to $8.1 million in the first quarter. Advertising fund revenues were $2.3 million, up 6.5% year over year. Software fees of $1.5 million improved 5.4% year over year. Franchise fees rose 26.3% year over year to $0.8 million.
The total cost of revenues amounted to almost $3 million, which escalated 9.9% year over year due to increased franchise and regional development. General and administrative expenses decreased 5.8% year over year to $6.9 million. However, total selling, general and administrative costs rose 8.8% year over year to $10.8 million.
The Joint incurred a net loss from continuing operations of $0.5 million, wider than the prior-year quarter’s $0.4 million.
System-wide sales rose 5% year over year to $132.6 million. As of March 31, 2025, the company’s total clinic count was 969, lower than the Zacks Consensus Estimate of 972. The number of franchised clinics totaled 847, which was in line with the consensus mark. However, company-owned or managed clinics were 122, lower than the consensus estimate of 125.
Adjusted EBITDA from net operations declined 18.6% year over year to $2.9 million. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)
The Joint’s Financial Update (as of March 31, 2025)
JYNT exited the first quarter with cash and cash equivalents of $21.9 million, which decreased from $25.1 million at the end of 2024.
Total assets of $77.2 million fell from $80.4 million at the end of 2024.
There was no reported debt under the credit agreement.
Total equity of $19.9 million rose 11.1% from the 2024-end level.
The Joint used net cash in operations of $3.7 million against net cash provided of $2.8 million in the prior year.
The Joint’s 2025 Guidance Reaffirmed
The company estimates that system-wide sales will remain in the range of $550-$570 million.
Adjusted EBITDA is projected between $10 and $11.5 million.
It expects to open 30-40 franchised clinics in 2025, down from 57 last year.
The Zacks Consensus Estimate for Encompass Health’s current-year earnings of $5.01 per share has witnessed one upward revision in the past seven days against none in the opposite direction. Encompass Health beat earnings estimates in each of the trailing four quarters, with the average surprise being 12.3%. The consensus estimate for current-year revenues is pegged at $5.9 billion, calling for 9.5% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of $1.09 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 145.8%. The consensus estimate for current-year revenues is pegged at $374.1 billion, calling for 22.5% year-over-year growth.
The Zacks Consensus Estimate for Adherex Technologies’ current-year earnings is pegged at 3 cents per share. Adherex Technologies has witnessed one upward revision in the past 30 days against none in the opposite direction. The consensus estimate for current-year revenues is pegged at $54.5 million, implying 14.7% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Joint Misses Q1 Earnings Estimates on Rising Expenses
The Joint Corp. (JYNT - Free Report) shares have declined 4.2% since the company reported first-quarter 2025 results on May 8. Its weaker-than-expected earnings were caused by increased expenses under different heads, partially offset by higher system-wide sales.
JYNT reported an adjusted loss of 3 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 2 cents. However, the bottom line remained stable year over year.
Revenues increased 7% year over year to $13.1 million. The top line surpassed the consensus mark by 2.5%.
The Joint Corp. Price, Consensus and EPS Surprise
The Joint Corp. price-consensus-eps-surprise-chart | The Joint Corp. Quote
JYNT’s Q1 Performance
Royalty fees advanced 6.4% year over year to $8.1 million in the first quarter. Advertising fund revenues were $2.3 million, up 6.5% year over year. Software fees of $1.5 million improved 5.4% year over year. Franchise fees rose 26.3% year over year to $0.8 million.
The total cost of revenues amounted to almost $3 million, which escalated 9.9% year over year due to increased franchise and regional development. General and administrative expenses decreased 5.8% year over year to $6.9 million. However, total selling, general and administrative costs rose 8.8% year over year to $10.8 million.
The Joint incurred a net loss from continuing operations of $0.5 million, wider than the prior-year quarter’s $0.4 million.
System-wide sales rose 5% year over year to $132.6 million. As of March 31, 2025, the company’s total clinic count was 969, lower than the Zacks Consensus Estimate of 972. The number of franchised clinics totaled 847, which was in line with the consensus mark. However, company-owned or managed clinics were 122, lower than the consensus estimate of 125.
Adjusted EBITDA from net operations declined 18.6% year over year to $2.9 million. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)
The Joint’s Financial Update (as of March 31, 2025)
JYNT exited the first quarter with cash and cash equivalents of $21.9 million, which decreased from $25.1 million at the end of 2024.
Total assets of $77.2 million fell from $80.4 million at the end of 2024.
There was no reported debt under the credit agreement.
Total equity of $19.9 million rose 11.1% from the 2024-end level.
The Joint used net cash in operations of $3.7 million against net cash provided of $2.8 million in the prior year.
The Joint’s 2025 Guidance Reaffirmed
The company estimates that system-wide sales will remain in the range of $550-$570 million.
Adjusted EBITDA is projected between $10 and $11.5 million.
It expects to open 30-40 franchised clinics in 2025, down from 57 last year.
JYNT’s Zacks Rank & Key Picks
JYNT currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Encompass Health Corporation (EHC - Free Report) and GeneDx Holdings Corp (WGS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. Another company, Adherex Technologies, Inc. (FENC - Free Report) , currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Encompass Health’s current-year earnings of $5.01 per share has witnessed one upward revision in the past seven days against none in the opposite direction. Encompass Health beat earnings estimates in each of the trailing four quarters, with the average surprise being 12.3%. The consensus estimate for current-year revenues is pegged at $5.9 billion, calling for 9.5% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of $1.09 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 145.8%. The consensus estimate for current-year revenues is pegged at $374.1 billion, calling for 22.5% year-over-year growth.
The Zacks Consensus Estimate for Adherex Technologies’ current-year earnings is pegged at 3 cents per share. Adherex Technologies has witnessed one upward revision in the past 30 days against none in the opposite direction. The consensus estimate for current-year revenues is pegged at $54.5 million, implying 14.7% year-over-year growth.